The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Edesa Biotech has an asset utilization ratio of 11.46 percent. This suggests that the company is making $0.11 for each dollar of assets. An increasing asset utilization means that Edesa Biotech is more efficient with each dollar of assets it utilizes for everyday operations.
The successful prediction of Edesa Biotech
stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published
stock prices of traded companies, such as Edesa Biotech, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at
the intrinsic value of Edesa Biotech based on Edesa Biotech hews, social hype, general headline patterns, and widely used
predictive technical indicators. We also calculate exposure to Edesa Biotech's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Edesa Biotech's related companies.
Use Technical Analysis to project Edesa expected Price
Edesa Biotech technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Edesa Biotech technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Edesa Biotech trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions.
More Info...Another Deeper Perspective
The current price rise of Edesa Biotech could raise concerns from investors as the firm closed today at a share price of
5.98 on
1,542,819 in volume. The company management teams may have good odds in positioning the firm resources to exploit market volatility in
September. The stock standard deviation of daily returns for 30 days investing horizon is currently 17.92. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Edesa Biotech partners.
Deferred Revenue Breakdown
Edesa Biotech Deferred Revenue is decreasing over the years with slightly volatile fluctuation. Ongoing Deferred Revenue is projected to grow to about 164.2
K this year. Deferred Revenue usually refers to a component of Total Liabilities representing the carrying amount of consideration received or receivable on potential earnings that were not recognized as revenue; including sales; license fees; and royalties; but excluding interest income. Edesa Biotech Deferred Revenue is projected to decrease significantly based on the last few years of reporting. The past year's Deferred Revenue was at 146,599
| 2010 | 173,333 |
| 2015 | 127,477 |
| 2019 | 146,599 |
| 2020 | 164,234 |
Over 3 percent rise for Edesa Biotech. What does it mean for investors?
Edesa Biotech current semi variance builds up over 36.62. Edesa Biotech is displaying above-average volatility over the selected time horizon. Investors should scrutinize Edesa Biotech independently to ensure intended market timing strategies are aligned with expectations about Edesa Biotech volatility.
Our Final Perspective on Edesa Biotech
Whereas many of the other players under the biotechnology industry are still a bit expensive, Edesa Biotech may offer a potential longer-term growth to investors. The inconsistency in the assessment between current Edesa valuation and our trade advice on Edesa Biotech is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Edesa Biotech.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Ellen Johnson is a Member of Macroaxis Editorial Board. Ellen covers public companies in North America, focusing primarily on valuation and volatility. Six years of experience in predictive investment analytics and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Edesa Biotech. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
